Cargando…
One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema
PURPOSE: Conbercept is a novel recombinant fusion protein designed as a decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor. The primary purpose was to investigate the effect and safety of conbercept, based on a practical protocol, in the eyes of patients with di...
Autores principales: | Zhou, Qingyun, Guo, Chao, You, Ailing, Wang, Desai, Wang, Wenyan, Zhang, Xuedong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817735/ https://www.ncbi.nlm.nih.gov/pubmed/31700228 |
Ejemplares similares
-
EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
por: Sun, Zuhua, et al.
Publicado: (2017) -
Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab
por: Xing, Peiyu, et al.
Publicado: (2023) -
Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema
por: Wang, Jing, et al.
Publicado: (2021) -
Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis
por: Sun, Xiaolei, et al.
Publicado: (2020) -
Intravitreal injection of conbercept combined with retinal photocoagulation on macular edema secondary to branch retinal vein occlusion
por: Wang, Bing, et al.
Publicado: (2020)